Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program
- PMID: 17996561
- DOI: 10.1016/j.jacc.2007.07.067
Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program
Abstract
Objectives: We explored the incidence and predictors of hyperkalemia in a broad population of heart failure patients.
Background: When used in optimal doses to treat patients with heart failure, renin-angiotensin-aldosterone system (RAAS) inhibitors improve clinical outcomes but can cause hyperkalemia.
Methods: Participants in the CHARM (Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity) (n = 7,599) Program were randomized to standard heart failure therapy plus candesartan or placebo, titrated as tolerated to a target of 32 mg once daily with recommended monitoring of serum potassium and creatinine. We assessed the incidence and predictors of hyperkalemia associated with dose reduction, study drug discontinuation, hospitalization, or death over the median 3.2 years of follow-up.
Results: Independent of treatment assignment, the risk of hyperkalemia increased with age > or =75 years, male gender, diabetes, creatinine > or =2.0 mg/dl, K+ > or =5.0 mmol/l, and background use of angiotensin-converting enzyme inhibitors or spironolactone. Candesartan increased the rate of aggregate hyperkalemia from 1.8% to 5.2% (difference 3.4%, p < 0.0001) and serious hyperkalemia (associated with death or hospitalization) from 1.1% to 1.8% (difference 0.7%, p < 0.001), with hyperkalemia associated with death reported in 2 (0.05%) candesartan patients and 1 (0.03%) placebo patient. The benefit of candesartan in reducing cardiovascular death or heart failure hospitalization (relative risk reduction 16%, p < 0.0001) was uniform in these subgroups, as was the incremental risk of hyperkalemia.
Conclusions: The risk of hyperkalemia is increased in symptomatic heart failure patients with advanced age, male gender, baseline hyperkalemia, renal failure, diabetes, or combined RAAS blockade. Although these groups derive incremental clinical benefit from candesartan, careful surveillance of serum potassium and creatinine is particularly important.
Similar articles
-
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.Circulation. 2004 Oct 26;110(17):2618-26. doi: 10.1161/01.CIR.0000146819.43235.A9. Epub 2004 Oct 18. Circulation. 2004. PMID: 15492298 Clinical Trial.
-
Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.Eur J Heart Fail. 2008 Feb;10(2):157-63. doi: 10.1016/j.ejheart.2007.12.006. Epub 2008 Jan 31. Eur J Heart Fail. 2008. PMID: 18242128 Clinical Trial.
-
Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.Eur Heart J. 2008 Dec;29(24):3022-8. doi: 10.1093/eurheartj/ehn476. Epub 2008 Nov 5. Eur Heart J. 2008. PMID: 18987098 Clinical Trial.
-
Angiotensin inhibition in heart failure.J Renin Angiotensin Aldosterone Syst. 2004 Sep;5 Suppl 1:S17-22. doi: 10.3317/jraas.2004.019. J Renin Angiotensin Aldosterone Syst. 2004. PMID: 15526237 Review.
-
[Benefits of candesartan in the treatment of symptomatic heart failure--CHARM programme].Nihon Rinsho. 2004 Jan;62(1):211-8. Nihon Rinsho. 2004. PMID: 14737855 Review. Japanese.
Cited by
-
Prevention and management of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors.CMAJ. 2021 Dec 6;193(48):E1836-E1841. doi: 10.1503/cmaj.210831. CMAJ. 2021. PMID: 34872955 Free PMC article. Review. No abstract available.
-
A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.Kidney Int. 2024 Mar;105(3):618-628. doi: 10.1016/j.kint.2023.11.025. Epub 2023 Dec 13. Kidney Int. 2024. PMID: 38101515 Free PMC article.
-
The kallikrein-kinin system in health and in diseases of the kidney.Kidney Int. 2009 May;75(10):1019-30. doi: 10.1038/ki.2008.647. Epub 2009 Feb 4. Kidney Int. 2009. PMID: 19190676 Free PMC article. Review.
-
Cardiac resynchronization therapy in CKD: a systematic review.Clin J Am Soc Nephrol. 2013 Aug;8(8):1293-303. doi: 10.2215/CJN.00750113. Epub 2013 May 9. Clin J Am Soc Nephrol. 2013. PMID: 23660183 Free PMC article.
-
Optimizing Therapies in Heart Failure: The Role of Potassium Binders.Biomedicines. 2022 Jul 16;10(7):1721. doi: 10.3390/biomedicines10071721. Biomedicines. 2022. PMID: 35885026 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical